Novel Analytical Method Development, Validation and Stability Study of Anticancer Drug Erlotinib in Tablet Dosage Form by RP-UFLC
K Purvini1, Chethan IA2, Jaishree Vaijanathappa2★★ Corresponding author
- 1Department of Pharmaceutical Analysis, Sri Adichunchanagiri College of Pharmacy, B. G. Nagara, Karnataka, INDIA.
- 2Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS AHER, Mysuru, Karnataka, INDIA.
CORRESPONDENCE
Jaishree Vaijanathappa
Dr. Jaishree V,Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS AHER, Mysuru-570015, Karnataka, INDIA.
Received: 29-05-2020; Revised: 02-12-2020; Accepted: 13-04-2021.
Volume 55, Issue 2S · pp. s589–s594 · PUBLISHED 2021 · DOI: 10.5530/ijper.55.2s.131
ABSTRACT
Present work is aimed to develop a novel, simple and accurate reverse phase-ultrafast liquid chromatographic (RP-UFLC) method for erlotinib (ELB) in tablet dosage form. The chromatogram was achieved by using Eclipse plus C18 column with methanol and water along with triethylamine (TEA 0.1%) as mobile phase (50:50 v/v) at a flow rate of 1 ml/min. The tablet dosage form was assayed, validated and subjected to degradation studies. The standard ELB possessed a retention time of 5.51 min and the developed method was linear in the concentration range of 10-100 µg/ml with r2≤0.99. Validation parameters have shown that the developed method was precise (%RSD < 1), accurate (recovery 98.50 to 99.52%) and robust. In the degradation studies, no extra products were observed in thermal conditions and a degraded product was observed in negligible percentage in basic and acidic conditions.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Purvini, K., IA, C., & Vaijanathappa, J. (2021). Novel Analytical Method Development, Validation and Stability Study of Anticancer Drug Erlotinib in Tablet Dosage Form by RP-UFLC. Indian Journal of Pharmaceutical Education and Research, 55(2S), s589–s594. https://doi.org/10.5530/ijper.55.2s.131
